Okładka

Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo

Recent advances in RNA interference (RNAi)-based drug development have partially allowed systemic administration of these agents in vivo with promising therapeutic effects. However, before chemically modified small-interfering RNAs (siRNAs) can be applied clinically, their in vivo effects should be...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
Główni autorzy:	Shunsuke Wada (Autor), Satoshi Obika (Autor), Masa-Aki Shibata (Autor), Tsuyoshi Yamamoto (Autor), Moeka Nakatani (Autor), Tetsuji Yamaoka (Autor), Hidetaka Torigoe (Autor), Mariko Harada-Shiba (Autor)
Format:	Książka
Wydane:	Elsevier, 2012-01-01T00:00:00Z.
Hasła przedmiotowe:	article
Dostęp online:	Connect to this object online.
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
od: Tsuyoshi Yamamoto, i wsp.
Wydane: (2012)

Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4' -BNA/LNA with 9-(aminoethoxy)phenoxazine
od: Taiki Matsubayashi, i wsp.
Wydane: (2024)

Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4'-BNA/LNA with 9-(aminoethoxy)phenoxazine
od: Taiki Matsubayashi, i wsp.
Wydane: (2024)

Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
od: Tsuyoshi Yamamoto, i wsp.
Wydane: (2021)

Targeting LDL Cholesterol With LNA
od: Arthur M Krieg
Wydane: (2012)

Electronic Structures of LNA Phosphorothioate Oligonucleotides
od: Henrik G. Bohr, i wsp.
Wydane: (2017)

Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides
od: Fumito Wada, i wsp.
Wydane: (2021)

Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes
od: Kiyoko Setoguchi, i wsp.
Wydane: (2017)

Investigating discovery strategies and pharmacological properties of stereodefined phosphorodithioate LNA gapmers
od: Jörg Duschmalé, i wsp.
Wydane: (2022)

Can Vitamin B12 Assist the Internalization of Antisense LNA Oligonucleotides into Bacteria?
od: Sara Pereira, i wsp.
Wydane: (2021)

Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice
od: Fatemeh Momen-Heravi, i wsp.
Wydane: (2021)

Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury
od: Pedro M.D. Moreno, i wsp.
Wydane: (2018)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
od: Punit P Seth, i wsp.
Wydane: (2012)

LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation
od: Asad Ali, i wsp.
Wydane: (2024)

Scaling approaches for the prediction of human clearance of LNA-i-mir-221: A retrospective validation
od: Massimiliano Fonsi, i wsp.
Wydane: (2024)

Comparative modeling, structure and active site prediction of Sclerotinia disease-resistant gene BnaMPK3 in Oilseed rape (Brassica napus)
od: Zeshan Haider, i wsp.
Wydane: (2020)

A Multifunctional LNA Oligonucleotide-Based Strategy Blocks AR Expression and Transactivation Activity in PCa Cells
od: Daniela Castanotto, i wsp.
Wydane: (2021)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
od: Maria Eugenia Gallo Cantafio, i wsp.
Wydane: (2016)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
Wydane: (2016)

Inhibition of Gastric Tumor Cell Growth Using Seed-targeting LNA as Specific, Long-lasting MicroRNA Inhibitors
od: Cathy Staedel, i wsp.
Wydane: (2015)

Dyslipidemia
Wydane: (2019)

Effective Osteogenic Priming of Mesenchymal Stem Cells through LNA-ASOs-Mediated <i>Sfrp1</i> Gene Silencing
od: Daniel García-Sánchez, i wsp.
Wydane: (2021)

PERTANGGUNGJAWABAN PIDANA TERHADAP PELAKU PENCEMARAN NAMA BAIK MELALUI MEDIA SOSIAL (STUDI KASUS TERHADAP PUTUSAN PERKARA NOMOR : 432/PID.SUS/2019/PN.BNA).
od: Husnatika Ayyasy,
Wydane: (2022)

PERBUATAN MELAWAN HUKUM TERKAIT PEMBATALAN HASIL PEMENANG LELANG PENGADAAN PICTURE ARCHIVING COMMUNICATION SYSTEM (Analisis Putusan Nomor: 59/PDT G 2017/PN BNA)
od: Rahmansyah,
Wydane: (2023)

Management of Dyslipidemia
Wydane: (2021)

Risk and dyslipidemia
od: Sadi Güleç
Wydane: (2018)

Dyslipidemia From Prevention to Treatment
Wydane: (2012)

Vitamin D supplementation is effective for olanzapine-induced dyslipidemia
od: Zijian Zhou, i wsp.
Wydane: (2023)

Dyslipidemia and Breast Cancer
od: Neelam Aggarwal, i wsp.
Wydane: (2018)

Office Management of Dyslipidemia
od: Gary Tabas, i wsp.
Wydane: (2010)

Dyslipidemias and obesity in Mexico
od: Simón Barquera, i wsp.
Wydane: (2007)

DYSLIPIDEMIA FEATURES IN CHILDREN
od: T. I. Turkinа, i wsp.
Wydane: (2016)

DYSLIPIDEMIA FEATURES IN CHILDREN
od: T. I. Turkinа, i wsp.
Wydane: (2016)

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
od: Alexey Berezhnoy, i wsp.
Wydane: (2012)

Antibody-siRNA conjugates (ARC): Emerging siRNA drug formulation
od: Weiran Cao, i wsp.
Wydane: (2022)

Applications of Scanning Electron Microscopy Using Secondary and Backscattered Electron Signals in Neural Structure
od: Daisuke Koga, i wsp.
Wydane: (2021)

Dyslipidemia and Hyperglycemia in Psoriatic Inpatients
od: Bojan Popchanovski, i wsp.
Wydane: (2019)

Dyslipidemia in women: etiology and management
od: Phan BAP, i wsp.
Wydane: (2014)

Bempedoic acid for the treatment of dyslipidemia
od: Joel C Marrs, i wsp.
Wydane: (2020)

Kelussia odoratissima Mozaffarian and dyslipidemia
od: Fatemeh Dehghan Shahreza
Wydane: (2017)